Security National Bank of SO Dak Buys 226 Shares of Johnson & Johnson (NYSE:JNJ)

Security National Bank of SO Dak grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,331 shares of the company’s stock after buying an additional 226 shares during the period. Johnson & Johnson makes up 1.5% of Security National Bank of SO Dak’s portfolio, making the stock its 22nd biggest position. Security National Bank of SO Dak’s holdings in Johnson & Johnson were worth $2,651,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. SGL Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 3.1% in the 4th quarter. SGL Investment Advisors Inc. now owns 31,481 shares of the company’s stock valued at $4,888,000 after buying an additional 940 shares in the last quarter. Shell Asset Management Co. grew its stake in Johnson & Johnson by 6.2% in the fourth quarter. Shell Asset Management Co. now owns 10,725 shares of the company’s stock valued at $1,551,000 after acquiring an additional 630 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $1,533,000. Silvercrest Asset Management Group LLC raised its position in shares of Johnson & Johnson by 17.2% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 626,808 shares of the company’s stock worth $90,649,000 after purchasing an additional 91,983 shares during the period. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 11.6% during the 4th quarter. Rafferty Asset Management LLC now owns 275,467 shares of the company’s stock valued at $39,838,000 after purchasing an additional 28,660 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ opened at $149.40 on Friday. The business’s 50-day simple moving average is $156.56 and its 200 day simple moving average is $154.00. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $359.47 billion, a PE ratio of 22.47, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Wells Fargo & Company dropped their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.